Table 2 Clinical data of the included studies in the systematic review
Author | Study design | Country | No | Cause | Age, years (Control vs Cytosorb) | Male, No (Control vs Cytosorb) | severity of disease of baseline (Control vs Cytosorb) | Pao2/Fio2 of baseline (Control vs Cytosorb) | duration of ECMO support, days (Control vs Cytosorb) | ICU length, days (Control vs Cytosorb) | Mortality, % (Control vs Cytosorb) |
|---|---|---|---|---|---|---|---|---|---|---|---|
Akil et al.[40] | Retrospective study | Germany | Control:10 Cytosorb:16 | COVID–19 | 62.2 ± 8.4 vs 58.5 ± 11.7 | 8 vs 10 | SAPS II score: 44.2 ± 10.7 vs 59.3 ± 9.1 | 85.8 ± 15.3 vs 103.4 ± 36.5 | 14.8 ± 12.0 vs 17.3 ± 17.1 | 15.5 ± 11.6 vs 26.5 ± 20.7 | 30% vs 37.5% (90–day mortality) |
Akil et al.[39] | Retrospective study | Germany | Control:7 Cytosorb:13 | sepsis | 61 ± 2 vs 61 ± 3 | 2 vs 5 | SAPS II score: 49.5 ± 2.2 vs 58.3 ± 2.13 | – | 19 ± 3 vs 8 ± 2 | 26 ± 5 vs 26 ± 6 | 57% vs 0% (30–day mortality) |
Rieder et al. [41] | Retrospective study | Germany | Control:9 Cytosorb:9 | unrestricted | 43.7 ± 13.4 vs 43.2 ± 13 | 6 vs 7 | SOFA score: 15 ± 7 vs 17 ± 2 RESP score: 1 ± 4 vs –7 ± –4.5 PRESERVE score: 4 ± 3.5 vs 6 ± 1.5 | – | – | 20.5 ± 7 vs 36 ± 75.5 | 77.8% vs 44.4% (ICU mortality) |
Supady et al. [35] | Randomized controlled trial | Germany | Control:17 Cytosorb:17 | COVID–19 | 59.0 (43.5–66.5) vs 62.0 (54.0–71.5) | 13 vs 12 | SOFA score: 9.0 (7.0–10.5) vs 9.0 (8.0–10.0) RESP score: 1.0 (0–3.5) vs 1.0 (0.5–2.0) PRESERVE score: 4.0 (2.0–6.0) vs 4.0 (3.0–5.0) | 84.2 (59.9–95.6) vs 62.7 (48.5–72.7) | – | – | 24% vs 82% (30–day mortality) |
Lebreton et al. [42] | Prospective study | France | Control:11 Cytosorb:11 | COVID–19 | 49(33–65) | 16 | SAPSII score: 46 (17–92) | – | 20(1–42) vs 25(6–56) | – | 36.4% vs 27.3% (60–day mortality) |
Kogelmann et al. [32] | Case series | Germany | 7 | sepsis | 51. ± 8.6 | 7 | SAPS score: 47.6 ± 8.6 SOFA score: 13.4 ± 1.7 | 89(range:55.5–120) | 8.7 ± 4 | 25.6 ± 17.8 | 42.9% (ICU mortality) |
Song et al. [43] | Retrospective Registry | USA | 52 | COVID–19 | 48(43–55) | 34 | SOFA score: 6.9 ± 3.87 | – | 31.6 ± 25.5 | – | 30.8% (ICU mortality) 17.3% (30–day mortality) 26.9% (90–day mortality) |
Geraci et al. [33] | Retrospective study | USA | 10 | COVID–19 | 45(37–51) | 9 | – | 85 (65–106) | 22 (13–64) | 47 (34–88) | 10% (90–day mortality) |